Lipoprotein lipase protects bovine endothelial cells from human NK cytotoxic activity.
Human lipoprotein lipase (LPL), in a dose dependent fashion, significantly inhibited spontaneous human natural killer (NK) cells, but not lymphokine-activated killer (LAK) cytotoxic activity against bovine pulmonary endothelial cells. The effect was dependent on endothelial heparan sulfate (HS) sites, since heparitinase reverted it. When HS is added before LPL, NK and LAK cytotoxicity are markedly reduced. Endothelial and NK cell priming, with LPL and HS+LPL, significantly induced CD40 and CD154 expression, respectively. Furthermore, CD40 expression was inversely proportional to lytic units (R2 = 0.9, P < 0.001). Treating endothelial cells simultaneously with indomethacin, CD154 fusion protein, and Wortmanin prevented the CD40 effect increasing xenograft rejection. LPL and HS+LPL protect bovine endothelial cells from NK cytotoxicity by inducing CD40, CD154 expression, and secretion of soluble factors. The high, non-modulated expression of adhesion receptors and the low number of HS sites account for the minor effect of CD40 in LAK cytotoxic responses against bovine endothelial cells.
De Sanctis
Juan B
JB
Instituto de Inmunología, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela. sanctisj@camelot.rect.ucv.ve
Arciniegas
Enrique
E
Bianco
Nicolás E
NE
D000818:Animals; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism; D002417:Cattle; D016861:Cyclooxygenase Inhibitors / Q000378:metabolism; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D042783:Endothelial Cells / Q000276:immunology* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology; D006497:Heparan Sulfate / Q000276:immunology; D006801:Humans; D007213:Indomethacin / Q000378:metabolism; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011993:Recombinant Fusion Proteins / Q000378:metabolism
D000954:Antigens, Surface; D016861:Cyclooxygenase Inhibitors; D006497:Heparan Sulfate; D007213:Indomethacin; D008071:Lipoprotein Lipase; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011993:Recombinant Fusion Proteins